

Susumu Takeuchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2690157/publications.pdf>

Version: 2024-02-01

25
papers

335
citations

1040056

9
h-index

888059

17
g-index

27
all docs

27
docs citations

27
times ranked

517
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). <i>International Journal of Clinical Oncology</i> , 2022, 27, 112-120.	2.2	9
2	Artificial intelligence analysis of three-dimensional imaging data derives factors associated with postoperative recurrence in patients with radiologically solid-predominant small-sized lung cancers. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 751-760.	1.4	9
3	Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma. <i>Molecular and Clinical Oncology</i> , 2022, 16, 87.	1.0	3
4	Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities. <i>Cancer Science</i> , 2022, 113, 2144-2166.	3.9	7
5	NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9110-9110.	1.6	0
6	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 7830.	3.3	50
7	Evaluation of a Tool that Enables Cancer Patients to Participate in the Decision-Making Process during Treatment Selection. <i>Journal of Nippon Medical School</i> , 2021, 88, 273-282.	0.9	1
8	ACTN4 gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. <i>Cancer Science</i> , 2021, , .	3.9	2
9	Lung cancer and obstructive lung disease in never smokers. <i>Journal of Thoracic Disease</i> , 2020, 12, 3934-3939.	1.4	0
10	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1052-1060.	1.9	36
11	Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1543-1548.	2.2	16
12	Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. , 2019, 7, 59.		9
13	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 165-173.	1.3	17
14	Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma. <i>Anticancer Research</i> , 2019, 39, 627-633.	1.1	9
15	Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 14896.	3.3	31
16	Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605.	2.0	7
17	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	2.0	10
18	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.4	23

#	ARTICLE	IF	CITATIONS
19	RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3295-3299.	1.1	8
20	Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy. <i>SpringerPlus</i> , 2016, 5, 2080.	1.2	9
21	Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 674-680.	1.3	6
22	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 241.	2.6	16
23	Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. <i>International Journal of Oncology</i> , 2014, 44, 1886-1894.	3.3	6
24	miR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma. <i>Oncology Reports</i> , 2014, 32, 2365-2372.	2.6	46
25	High Survival Rate of 6 Cases of Pulmonary Large Cell Neuroendocrine Carcinoma Formerly Classified as Small Cell Carcinoma.. <i>Journal of Nippon Medical School</i> , 2001, 68, 335-339.	0.9	5